EUVIMEDEUVIMED entdecken
Crossref

The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma

Xue Chen iD, Shujun Guo, Qilin Meng, Junye Xie, Yujie Xiao, Yuanmeng Sun, Jinchi Yao, Xinyi Jiang, An Hong, Xiaojia Chen

IUBMB Life · 2025

DOI: 10.1002/iub.70014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Xue Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Guangdong S&T Program, National Natural Science Foundation of China, the Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) accounts for 75%–85% of primary liver cancer cases globally. HCC patients have a poor prognosis because of tumor metastasis and medication resistance; thus, novel therapy targets and techniques are needed. By using the Kaplan–Meier plotter database, we identified a strong association between midkine (MDK) and HCC mortality and validated its high expression in numerous HCC cell lines. In vitro, MDK down‐regulation decreased HCC cell growth and macrophage M2‐type polarization, whereas the presence of the MDK factor led to an increase in these processes. Combined with the first‐line chemotherapeutic agent for HCC, Lenvatinib, zebrafish experiments showed that the inhibitor iMDK inhibited the growth of intersegmental vessels and subintestinal vessels, while also mitigating the pericardial edema side effect. In a subcutaneous mouse model, the combination of iMDK with Lenvatinib inhibited HCC growth, angiogenesis, and M2‐type macrophage infiltration. These results indicate that MDK represents a promising therapeutic target for HCC. Furthermore, the combination of iMDK with Lenvatinib enhances HCC inhibition, thereby presenting a novel therapy option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesMidkineAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansMiceCell ProliferationZebrafishXenograft Model Antitumor AssaysCell Line, TumorGene Expression Regulation, NeoplasticMacrophagesNeovascularization, PathologicMice, Nude

Stichwörter der Autor:innen

Lenvatinibcombinationhepatocellular carcinomamidkine inhibitortherapeutic target

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesMidkineMDK protein, human

Autor:innen und Institutionen

  • Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou, China.
  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
  • National Engineering Research Center of Genetic Medicine, Guangzhou, China.
  • Guangdong Province Key Laboratory of Bioengineering Medicine, Guangzhou, China.
  • Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center, Guangzhou, China.
  • MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.

ORCID-Profile: Xue Chen

Förderung

  • Guangdong S&T Program
  • National Natural Science Foundation of China
  • the Guangdong Basic and Applied Basic Research Foundation
  • Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation ("Climbing Program" Special Funds)

Zitieren

APA

Chen, X., Guo, S., Meng, Q., Xie, J., Xiao, Y., Sun, Y., Yao, J., Jiang, X., Hong, A., & Chen, X. (2025). The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma. IUBMB Life. https://doi.org/10.1002/iub.70014

Vancouver

Chen X, Guo S, Meng Q, Xie J, Xiao Y, Sun Y, et al. The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma. IUBMB Life. 2025. doi:10.1002/iub.70014

BibTeX
@article{Chen2025,
  author = {Chen, Xue and Guo, Shujun and Meng, Qilin and Xie, Junye and Xiao, Yujie and Sun, Yuanmeng and Yao, Jinchi and Jiang, Xinyi and Hong, An and Chen, Xiaojia},
  title = {The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.70014}
}
Kostenlos starten →